Madden Kate, Feldman Henry A, Chun Rene F, Smith Ellen M, Sullivan Ryan M, Agan Anna A, Keisling Shannon M, Panoskaltsis-Mortari Angela, Randolph Adrienne G
1 Department of Anesthesia, Perioperative and Pain Medicine, Division of Critical Care Medicine.
2 Department of Anaesthesia and.
Ann Am Thorac Soc. 2015 Nov;12(11):1654-61. doi: 10.1513/AnnalsATS.201503-160OC.
Vitamin D deficiency, often defined by total serum 25-hydroxyvitamin D (25[OH]D) <20 ng/ml, is common in critically ill patients, with associations with increased mortality and morbidity in the intensive care unit. Correction of vitamin D deficiency in critical illness has been recommended, and ongoing clinical trials are investigating the effect of repletion on patient outcome. The biologically active amount of 25(OH)D depends on the concentration and protein isoform of vitamin D-binding protein (VDBP), which is also an acute-phase reactant affected by inflammation and injury.
We performed a secondary analysis of a cohort of critically ill children in which we reported a high rate of vitamin D deficiency, to examine how VDBP level and genotype would impact vitamin D status.
We prospectively enrolled 511 children admitted to the pediatric intensive care unit over a 12-month period.
We measured serum VDBP in 479 children. We genotyped single nucleotide polymorphisms rs7041 and rs4588 in the VDBP gene (GC) to determine haplotypes GC1F, GC1S, and GC2 in 178 subjects who consented, then calculated bioavailable 25(OH)D from serum 25(OH)D, VDBP, albumin, and GC haplotype. The median serum VDBP level was 159 μg/ml (interquartile range, 108-221), lower than has been reported in healthy children. Factors predicting lower levels in multivariate analysis included age <1 year, nonwhite race, being previously healthy, 25(OH)D <20 ng/ml and greater illness severity. In the subgroup that was genotyped, GC haplotype had the strongest association with VDBP level; carriage of one additional copy of GC1S was associated with a 37.5% higher level (95% confidence interval, 31.9-44.8; P < 0.001). Bioavailable 25(OH)D was also inversely associated with illness severity (r = -0.24, P < 0.001), and ratio to measured total 25(OH)D was variable and related to haplotype.
Physiologic deficiency of 25(OH)D in critical illness may be more difficult to diagnose, given that lower VDBP levels increase bioavailability. Treatment studies conducted on the basis of total 25(OH)D level, without consideration of VDBP concentration and genotype, may increase the risk of falsely negative results.
维生素D缺乏症通常定义为血清总25-羟基维生素D(25[OH]D)<20 ng/ml,在重症患者中很常见,与重症监护病房中死亡率和发病率增加相关。已建议纠正危重病中的维生素D缺乏症,并且正在进行的临床试验正在研究补充维生素D对患者预后的影响。25(OH)D的生物活性量取决于维生素D结合蛋白(VDBP)的浓度和蛋白质异构体,VDBP也是一种受炎症和损伤影响的急性期反应物。
我们对一组重症儿童进行了二次分析,我们曾报道该组儿童维生素D缺乏率很高,以研究VDBP水平和基因型如何影响维生素D状态。
我们前瞻性纳入了12个月内入住儿科重症监护病房的511名儿童。
我们测量了479名儿童的血清VDBP。我们对VDBP基因(GC)中的单核苷酸多态性rs7041和rs4588进行基因分型,以确定178名同意参与的受试者的单倍型GC1F、GC-1S和GC2,然后根据血清25(OH)D、VDBP、白蛋白和GC单倍型计算生物可利用的25(OH)D。血清VDBP水平中位数为159 μg/ml(四分位间距,108-221),低于健康儿童的报道水平。多变量分析中预测较低水平的因素包括年龄<1岁、非白人种族、既往健康、25(OH)D<20 ng/ml以及病情严重程度更高。在进行基因分型的亚组中,GC单倍型与VDBP水平的关联最强;携带额外一份GC1S与水平高37.5%相关(95%置信区间,31.9-44.8;P<0.001)。生物可利用的25(OH)D也与病情严重程度呈负相关(r=-0.24,P<0.001),与测得的总25(OH)D的比值可变且与单倍型有关。
鉴于较低的VDBP水平会增加生物利用度,危重病中25(OH)D的生理缺乏可能更难诊断。在不考虑VDBP浓度和基因型的情况下,基于总25(OH)D水平进行的治疗研究可能会增加假阴性结果的风险。